Adoptive Immunotherapy for Cancer: Harnessing the T Cell Response

Overview

Journal Nat Rev Immunol

Specialty Allergy & Immunology

Date 2012 Mar 23

PMID 22437939

Citations 854

Authors

Nicholas P Restifo

Mark E Dudley

Steven A Rosenberg

Affiliations

Soon will be listed here.

Abstract

Immunotherapy based on the adoptive transfer of naturally occurring or gene-engineered T cells can mediate tumour regression in patients with metastatic cancer. Here, we discuss progress in the use of adoptively transferred T cells, focusing on how they can mediate tumour cell eradication. Recent advances include more accurate targeting of antigens expressed by tumours and the associated vasculature, and the successful use of gene engineering to re-target T cells before their transfer into the patient. We also describe how new research has helped to identify the particular T cell subsets that can most effectively promote tumour eradication.

Citing Articles

Luteolin as an adjuvant effectively enhanced the efficacy of adoptive tumor-specific CTLs therapy.

Lai Z, Pang Y, Zhou Y, Chen L, Zheng K, Yuan S BMC Cancer. 2025; 25(1):411.

PMID: 40050776 PMC: 11887225. DOI: 10.1186/s12885-025-13831-8.

Intra-Tumoral Lymphocytic Infiltration Is Associated with Favorable Prognosis in Suboptimal Surgery in High-Grade Serous Ovarian Carcinoma.

Harada H, Hachisuga T, Harada Y, Shibahara M, Murakami M, Nuratdinova F Diagnostics (Basel). 2025; 15(4).

PMID: 40002574 PMC: 11854212. DOI: 10.3390/diagnostics15040422.

CD8 + T cells may mediate the effect of gut microbiota on psoriasis: evidence from two-step mendelian randomization and bayesian weighting.

Li X, Wu Y, Chen S, Deng C, Cheng S, Yan Z Arch Dermatol Res. 2025; 317(1):370.

PMID: 39921729 DOI: 10.1007/s00403-025-03857-0.

Exploring the role and mechanisms of MAGEA4 in tumorigenesis, regulation, and immunotherapy.

Zhu W, Yi Q, Chen Z, Wang J, Zhong K, Ouyang X Mol Med. 2025; 31(1):43.

PMID: 39905312 PMC: 11796067. DOI: 10.1186/s10020-025-01079-8.

Isolation of a tumor neoantigen specific CD8+ TCR from a skin biopsy of a vaccination site.

Roberti M, Charoentong P, Lyu Y, Meyer M, Eichmuller S, Schmidt P Oncoimmunology. 2025; 14(1):2457793.

PMID: 39902862 PMC: 11796541. DOI: 10.1080/2162402X.2025.2457793.

References

Chen P, Wang M, Bronte V, Zhai Y, Rosenberg S, Restifo N . Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol. 1996; 156(1):224-31. PMC: 1950465. View

Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View

Gattinoni L, Klebanoff C, Palmer D, Wrzesinski C, Kerstann K, Yu Z . Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005; 115(6):1616-26. PMC: 1137001. DOI: 10.1172/JCI24480. View

Klebanoff C, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones A, Finkelstein S . Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005; 102(27):9571-6. PMC: 1172264. DOI: 10.1073/pnas.0503726102. View

Wang M, Bronte V, Chen P, Gritz L, Panicali D, Rosenberg S . Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol. 1995; 154(9):4685-92. PMC: 1976248. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

Gattinoni L, Finkelstein S, Klebanoff C, Antony P, Palmer D, Spiess P . Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005; 202(7):907-12. PMC: 1397916. DOI: 10.1084/jem.20050732. View

NORTH R . Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982; 155(4):1063-74. PMC: 2186638. DOI: 10.1084/jem.155.4.1063. View

Khong H, Restifo N . Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002; 3(11):999-1005. PMC: 1508168. DOI: 10.1038/ni1102-999. View

10.

Kawakami Y, Eliyahu S, Delgado C, Robbins P, Rivoltini L, Topalian S . Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994; 91(9):3515-9. PMC: 43610. DOI: 10.1073/pnas.91.9.3515. View

11.

Chapuis A, Thompson J, Margolin K, Rodmyre R, Lai I, Dowdy K . Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A. 2012; 109(12):4592-7. PMC: 3311364. DOI: 10.1073/pnas.1113748109. View

12.

Frankel T, Burns W, Peng P, Yu Z, Chinnasamy D, Wargo J . Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J Immunol. 2010; 184(11):5988-98. PMC: 6290481. DOI: 10.4049/jimmunol.1000189. View

13.

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

14.

Jorritsma A, Schotte R, Coccoris M, de Witte M, Schumacher T . Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther. 2011; 11(4):276-87. DOI: 10.2174/156652311796150390. View

15.

Chinnasamy N, Wargo J, Yu Z, Rao M, Frankel T, Riley J . A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol. 2010; 186(2):685-96. PMC: 6292200. DOI: 10.4049/jimmunol.1001775. View

16.

Irvine K, Chamberlain R, Shulman E, Surman D, Rosenberg S, Restifo N . Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst. 1997; 89(21):1595-601. DOI: 10.1093/jnci/89.21.1595. View

17.

Leitner W, Hwang L, DeVeer M, Zhou A, Silverman R, Williams B . Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med. 2002; 9(1):33-9. PMC: 1484510. DOI: 10.1038/nm813. View

18.

Hofmann O, Caballero O, Stevenson B, Chen Y, Cohen T, Chua R . Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A. 2008; 105(51):20422-7. PMC: 2603434. DOI: 10.1073/pnas.0810777105. View

19.

Stephan M, Ponomarev V, Brentjens R, Chang A, Dobrenkov K, Heller G . T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007; 13(12):1440-9. DOI: 10.1038/nm1676. View

20.

Bluestone J . The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med. 2011; 365(22):2129-31. DOI: 10.1056/NEJMe1110900. View